Killing Hypoxic Cell Populations in a 3D Tumor Model with EtNBS-PDT by Evans, Conor L. et al.
Killing Hypoxic Cell Populations in a 3D Tumor Model
with EtNBS-PDT
Conor L. Evans
1, Adnan O. Abu-Yousif
1, Yong Jin Park
2, Oliver J. Klein
1, Jonathan P. Celli
1, Imran Rizvi
1,
Xiang Zheng
1, Tayyaba Hasan
1*
1Wellman Center for Photomedicine, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 2Department of
Chemical and Biomolecular Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea
Abstract
An outstanding problem in cancer therapy is the battle against treatment-resistant disease. This is especially true for ovarian
cancer, where the majority of patients eventually succumb to treatment-resistant metastatic carcinomatosis. Limited
perfusion and diffusion, acidosis, and hypoxia play major roles in the development of resistance to the majority of front-line
therapeutic regimens. To overcome these limitations and eliminate otherwise spared cancer cells, we utilized the cationic
photosensitizer EtNBS to treat hypoxic regions deep inside in vitro 3D models of metastatic ovarian cancer. Unlike standard
regimens that fail to penetrate beyond ,150 mm, EtNBS was found to not only penetrate throughout the entirety of large
(.200 mm) avascular nodules, but also concentrate into the nodules’ acidic and hypoxic cores. Photodynamic therapy with
EtNBS was observed to be highly effective against these hypoxic regions even at low therapeutic doses, and was capable of
destroying both normoxic and hypoxic regions at higher treatment levels. Imaging studies utilizing multiphoton and
confocal microscopies, as well as time-lapse optical coherence tomography (TL-OCT), revealed an inside-out pattern of cell
death, with apoptosis being the primary mechanism of cell killing. Critically, EtNBS-based photodynamic therapy was found
to be effective against the model tumor nodules even under severe hypoxia. The inherent ability of EtNBS photodynamic
therapy to impart cytotoxicity across a wide range of tumoral oxygenation levels indicates its potential to eliminate
treatment-resistant cell populations.
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Introduction
The last several decades have seen countless advances in our
ability to detect and treat cancer. However, the mortality associ-
ated with certain cancers, such as ovarian, remains unacceptably
high. Ovarian cancer (OvCa) represents a major therapeutic
challenge, as tumors too often evade front-line treatments, causing
the majority of patients to eventually succumb to treatment-resistant
disease. Problematically, OvCa is typically diagnosed at an advanced
stage, where patients present with disseminated metastatic lesions
coatingthesurfacesoftheperitonealcavity.Itisimpossibletoremove
all lesions surgically, leaving behind significant sub-millimeter sized
residual tumors. Women with recurrent, resistant OvCa face a poor
quality of life and a dismal five-year survival rate of 30% [1].
In an attempt to eradicate these tumors, physicians turn to a
toolkit of therapies that can be tailored for specific cancers, and
increasingly, specific patients. Combination OvCa regimens, such
as carboplatin-paclitaxel therapy, have resulted in moderate
patient survival improvements [1], with intraperitoneal (i.p.)
administration currently being the preferred method at most
institutions. However, numerous factors can limit the delivery of
i.p. therapeutics into OvCa nodules, including the structure and
charge of the agent, physiological factors such as permeability, and
the presence of tumor stroma, rich in extracellular matrix (ECM)
[2]. Intravenous therapeutics also suffer from limited uptake as
tumors have disorganized, leaky, and branched vessel networks
with high interstitial pressure [3,4].
Poor tissue perfusion and diffusion leads to the hypoxia observed
in tumors [5,6] such as metastatic OvCa lesions [7]. Diffusion
typically allows for only ,70 mm of gas penetration, resulting in
widespread oxygen-depleted tumor regions [8]. Hypoxia triggers an
array of cellular defense mechanisms, many of which are activated
by the hypoxia-inducible transcriptionfactor 1, that protect hypoxic
tumor cells from potent therapies [9]. These mechanisms render
front-line agents for OvCa, such as carboplatin and paclitaxel,
ineffective in hypoxic environments [10], with paclitaxel demon-
strated to be over 100 times less effective under hypoxic conditions
[11]. Without the ability to produce radicals through oxygen
consumption, radiation therapy also loses its cytotoxic potential
under hypoxia [9]. Furthermore, anaerobic glycolysis causes tumor
acidification [12,13], substantially altering the uptake of chemo-
therapeutics and conferring chemoresistance against certain agents
[14]. Therapeutics, therefore, often inadequately treat subpopula-
tions of cancer cells, leading to the proliferation of chemorefractive
or chemoresistant disease. To eliminate this surviving population, it
is imperative to expand the physicians’ treatment toolkit with
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therapeutic agents must pass through the ECM, rapidly permeate
through cell layers, and uptake into cells. Importantly, any
therapeutic needs to be highly effective in both normoxic and
hypoxic environments, and must evade cancer cells’ typically up-
regulated anti-apoptotic machinery.
Treatments based on photodynamic therapy (PDT) have the
ability to address these requirements. An FDA-approved cancer
treatment, PDT uses molecules known as photosensitizers that
generate cytotoxic reactive species when exposed to particular
wavelengths of light [15]. PDT is particularly apt for cancer
treatment as photosensitizers selectively accumulate in cancerous
lesions and the therapy is limited only to irradiated tissues. PDT of
OvCa patients using the first generation, non-specific photosen-
sitizer Photofrin, which although suboptimal, was found to confer
a significant survival advantage [16]. The second-generation
photosensitizer BPD (benzoporphyrin derivative monoacid A)
showed promise in vivo [17] and has been found to be synergistic
with chemotherapy [18] and biological therapies [19]. PDT with
BPD has been observed to be effective even against drug-resistant
OvCa [20]. A major drawback using these porphyrin-based
photosensitizers, however, is that they also suffer from penetration
problems and require molecular oxygen to impart cytotoxicity,
meaning that hypoxic tumor regions are still protected against
these powerful agents.
Building upon early studies with cationic phenothiazinium
molecules, this work demonstrates that PDT is capable of
effectively treating deep, hypoxic tumor cell populations when
using a molecule from a different class of photosensitizers. Here we
use the small cationic, methylene blue-like molecule EtNBS (5-
ethylamino-9-diethyl-aminobenzo[a]phenothiazinium chloride),
which is rapidly taken up by cancer cells and malignant tissues
and achieves maximum concentration in tumors at 3 hours
following subcutaneous injection [21,22]. While EtNBS concen-
trates primarily in lysosomes, upon activation with red light (640–
660 nm) it can burst out of these compartments and react
throughout the cell [23]. EtNBS-PDT has been studied and found
safe in animal experiments where it was observed to confer
significant treatment benefits [22,24]. EtNBS can mediate its
phototoxicity through a molecular-oxygen dependent, singlet
oxygen mediated (‘‘Type II’’) mechanism with 3% efficiency [25].
Importantly, EtNBS is also able to impart cytotoxicity without
consuming oxygen (‘‘Type I’’ photosensitization), making it an
attractive therapy for treating cellular subpopulations of hypoxic
cancer cells. In this mechanism, the excited molecule creates
cytotoxic radical species by directly interacting with biomolecules
and water, creating lipid and protein radical species, as well as
hydroxyl radicals and superoxide species [22]. These cytotoxic
moieties diffuse and react with surrounding organelles and cellular
structures, triggering apoptosis. This gives EtNBS the ability to
mediate its cytotoxic effects through two different photochemical
channels, which is of critical importance when treating cells in both
normoxic and hypoxic environments. This property of EtNBS has
not yet been exploited to treat therapeutically-resistant tumor regions.
By combining the treatment of 3D in vitro models of OvCa with
optical imaging approaches, here we show that EtNBS can effectively
treat otherwise protected and unresponsive cellular populations.
Results
The 3D Model Recapitulates Physiological Treatment
Resistance Mechanisms
Monolayer culture systems are useful in providing insight into
cellular-level treatment response, with animal models often used to
validate therapeutic efficacy on a large scale. Both approaches,
however, can miss critical time-sensitive and spatial information.
In contrast, 3D in vitro tumor models provide many critical cell
signaling cues to recapitulate in vivo features while retaining the
capability for real-time, cellular-level imaging for therapeutic
uptake and response. The 3D adherent OvCa model used in this
study was specifically created to model the multitude of avascular
metastatic tumors that coat surfaces of the peritoneal cavity
[18,26,27]. In this system, OvCa cells were cultured on the surface
of an ECM-rich gel bed (Matrigel), and developed into nodules
varying in sizes over the course of days. Previous studies using such
in vitro 3D models have predominately utilized small adherent 3D
cultures (40–150 mm diameter), which do not adequately address
clinically-relevant treatment deficits such as limited drug penetra-
tion and hypoxia [1]. To probe these critical problems, we grew
the adherent OvCa model for a period of 13 days to achieve a
population of large nodules that are .200 mm in diameter [26].
Poor diffusion into large nodules is a major impediment in Platin-
based therapy, where compounds such as cisplatin were found to
localize at the nodule periphery, with much lower concentrations
in the nodule core [28]. In our 3D OvCa model, we found that the
anionic photosensitizer BPD diffused weakly into nodules during
1.5 hours of incubation, primarily concentrating in the nodule
periphery with a penetration depth about 125 mm (Figures 1A,B).
Even after an incubation period three times this standard duration,
the majority of BPD was still localized on the nodule surface
(Figures 1C,D), sparing cells deep in the model tumor.
One component that limits therapeutic penetration is the
extracellular matrices (ECM) that are present in the tumor
Figure 1. Uptake of the photosensitizer BPD over 1.5 and
4.5 hours. Images (A) and (B) are from a sample incubated with BPD
for 1.5 hours; images (C) and (D) are from a 4.5 hour incubation. (A)
Transmission image of two OvCa nodules following cryosection. The
thickness of the slice was 30 mm. Matrigel can be seen attached to the
nodules in the bottom-left portion of the image. (B) Confocal image of
BPD fluorescence in the nodule, revealing its limited uptake into the
nodules. (C) DIC image of a similarly prepared 30 mm slice through an
OvCa nodule. (D) BPD fluorescence image, showing that even after
4.5 hours, the majority of BPD is retained in the periphery of large
nodules.
doi:10.1371/journal.pone.0023434.g001
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stained for three common ECM proteins that are important in
metastatic OvCa: fibronectin, collagen IV, and laminin V [29]. As
seen in Figures 2A–C, all three ECM proteins are observed to coat
the exterior of the nodule, forming a physical barrier to
therapeutic delivery. GM130 staining of the Golgi apparatus
reveals that the outermost layer of cells in contact with the ECM
share a common apical polarity, while cells in the center of the
nodule show random polarity. This apical polarity is an
organizational feature observed in 3D in vitro tumor cultures and
is thought to be due to the interaction of cells with the coat of the
ECM proteins [30]. This ECM barrier most likely plays a critical
role in the penetration of platin chemotherapeutics, and traps BPD
at the nodule surface, as seen in Figure 1D.
Even if therapeutics can penetrate into the nodule, their efficacy
can still be severely hampered by the presence of hypoxia. Oxygen
diffusionstudiesindicatedthepossibilitythattheOvCanoduleslikely
had hypoxic cores [31]. By imaging nodules stained with pimoni-
dazole using two-photon microscopy, we found a consistent pattern
of hypoxia throughout the cores of our in vitro OvCa nodules larger
than 200 mm in diameter (Figure 2D). The pH gradients caused by
hypoxia-induced acidification of the tumor microenvironment can
alsohavea major effecton treatment byaltering the partitioning and
uptake of therapeutics into cells [32]. pH gradients in living OvCa
nodules were visualized using the spectral-ratiometric pH imaging
agent SNARF-4F (Figure 2E). A clear pH gradient was observed
along the radii of nodules, with the pH ranging from neutral at the
nodule periphery to levels below six in nodule cores. These acidic
cores were consistentlyobserved across both smalland large nodules,
indicating the widespread presence of acidosis.
To visualize the impact of these therapeutic limitations in the 3D
OvCa model, the large nodules were treated with either carboplatin
or BPD-PDT. The nodules were observed to have spatially
conserved patterns of cytotoxicity (Figure 3). Nodules treated with
carboplatin were observed to have only peripheral cellular death
leaving a surviving core (Figure 3B), consistent with earlier studies
[18,26,27]. PDT with the photosensitizer BPD was also observed to
primarily kill cells at the exterior of large nodules, sparing nodule
core cells (Figure 3C). This outside-only treatment response pattern
was observed across numerous therapeutic doses (data not shown).
As therapeutically-resistant cancer is understoodto evolve from cells
that escapetreatment,thismodel’s surviving nodularcore cellslikely
recapitulate a subpopulation of cells in vivo that are protected from
treatment and may develop into resistant carcinoma.
EtNBS rapidly concentrates into nodule core cell
populations
To effectively eliminate these spared nodule cell populations, we
synthesized and administered the small cationic photosensitizer
EtNBS to the 3D model system. Pre-treatment (dark) toxicity
experiments were carried out to determine the optimal adminis-
tration concentration of EtNBS. From these studies, the ideal
balance between dark toxicity and effective therapeutic concen-
tration was found at a concentration of 500 nM (data not shown).
In stark contrast to the previously described treatment regimens,
EtNBS was observed to rapidly diffuse throughout model metastatic
nodules (Figure 4A–E, Video S1). Rapid uptake into the nodules’
periphery was observed almost instantly, with EtNBS filling nodules
completely within a five hour period. Importantly, the observed
uptake timescale in the model nodules optimally matches what has
been found safe in animal experiments, where maximum tumor
concentrations were reached in three hours with a clearance time of
24 hours [22]. Based on these results, a 4.5 hour EtNBS incubation
time was selected for all future experiments.
To visualize the actual (not optical) uptake pattern of EtNBS in
the metastatic OvCa model, 3D cultures incubated with EtNBS
were cyrosectioned into 30 mm slices. A representative image of a
Figure 2. Physiological factors can cause poor therapeutic outcomes in metastatic OvCa nodules. Large nodules stained for the
presence of ECM show coatings of human fibronectin (A), collagen IV (B), and laminin V (C), in red. Cell nuclei were stained with DAPI (blue). Staining
with the Golgi protein GM130 (C, green) reveals that the outer nodule cell layer is polarized. Multiphoton microscopy of PIM-stained, day 13 nodules
reveals the presence of hypoxic core cells (D, false color). pH imaging using SNARF-4F shows that the core of the model nodules are acidic (E).
Autofluorescence gave rise to the two deeply acidic (pH,5.5) point artifacts in the center of the image.
doi:10.1371/journal.pone.0023434.g002
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Figure 4F. Importantly, EtNBS is seen to selectively concentrate
into the nodule core, the very region that typically evades therapy
due to poor therapeutic uptake. This uptake intensity pattern
matches nodular regions observed to be acidic (Figure 2E),
suggesting that the cationic photosensitizer diffuses along the acidic
pH gradient, concentrating in cells within the acidic nodule core.
EtNBS therapy kills nodule core cells and becomes
increasingly more effective with increasing nodule size
We next investigated the efficacy of EtNBS-PDT on large model
OvCa nodules. Using the live-dead viability assay, the LD50 for 13-
dayoldnoduleswasfoundtobeachievedatalightdoseof20 J/cm
2,
a fraction of what is typically used in animal studies [24] (Figure 5A).
Importantly, even at the low light dose of 5 J/cm
2, EtNBS was able
to selectively destroy normally protected nodule core cells
(Figure 5B). This spatial pattern of EtNBS treatment response
correlates with its uptake pattern (Figure 3F), demonstrating that
EtNBS is capable of both concentrating into and killing otherwise
untreated, hypoxic cellular populations. Moreover, the EtNBS
treatment response pattern is exactly opposite of what has been
observed using the peripheral-localizing therapies carboplatin and
BPD (Figure 3). At higher light doses, EtNBS-PDT is observed to
trigger cellular killing across entire avascular model nodules as large
as 600 mm (Figure 5C). Staining with ApoTRACE revealed that
these cells treated with EtNBS-PDT died via apoptosis (Figure S1).
To explore whether the cytotoxicity of EtNBS is dependent on
nodule size, cultures were grown for 7, 10, and 13 days to generate
nodules across a large range of diameters from 50 to 600 mmi ns i z e .
Half of the nodules were incubated with EtNBS, while for
comparison, the other half were incubated with the periphery-
localizing photosensitzer BPD. Nodules were then treated with PDT
at a light dose of 10 J/cm
2, and the resulting live/dead images were
segmented to calculate the live:dead ratiofor each individual nodule.
The efficacy of BPD-PDT is observed to decrease with nodule size,
consistent with its limited penetration depth. In contrast, EtNBS’s
uptake and cytotoxicity in the otherwise treatment-resistant core
becomes increasingly beneficial with increasing nodule size
(Figure 5D), likely because larger nodules have a greater portion of
their cells buried in increasingly large acidic cores.
To better understand the complex treatment pattern and
continuously visualize nodules’ response to therapy, time lapse
optical coherence tomography [26] (TL-OCT) imaging was
carried out during the 24 hours immediately following EtNBS-
PDT at 10 J/cm
2. A highly sensitive cross-sectional imaging
technology, TL-OCT enables label-free, non-destructive structural
imaging of the large in vitro nodules over the course of many days.
In the cross-sectional TL-OCT video, nodules are observed to
immediately rupture from the inside-out within 5 hours of
treatment, with numerous highly scattering apoptotic bodies
pouring out of the nodules into the overlaying media (Figure 6,
Video S2). This is in sharp contrast to large nodules treated with
periphery-concentrating platin chemotherapeutics [26] or BPD
[33], where only the nodule periphery was observed to undergo
apoptosis, leaving behind surviving cores.
The two phototoxicity mechanisms of EtNBS give rise to
irradiance-dependent spatial killing patterns
EtNBS can impart cytotoxicity via two different photocytotoxi-
city mechanisms: the Type I, radical-mediated pathway, and the
Type II, oxygen-consuming mechanism. As the Type II channel
can consume and thus deplete molecular oxygen, EtNBS has the
ability to treat normoxic and hypoxic cellular populations as a
function of irradiance. Day 13 cultures incubated with EtNBS
were treated across a range of irradiances for total fluence of 15 J/
cm
2 (Figure 7). Maximum cellular killing was observed at the
lowest irradiance of 25 mW/cm
2 and cellular viability was
observed to increase with irradiance, reaching an asymptote at
100 mW/cm
2 (Figure 7A). This decrease in treatment efficacy
strongly correlates with changes in the pattern of nodule cellular
death. At the low irradiances of 25 mW/cm
2, EtNBS-PDT is
capable of treating entire nodules, triggering apoptosis in both
nodule cores and peripheries (Figure 7B). However, at moderate to
high levels of irradiance (50–300 mW/cm
2), when oxygen is more
rapidly depleted, EtNBS is observed to instead cause only nodule
core death (Figure 7C) through its primarily oxygen-independent
Figure 3. The cores of large OvCa nodules survive carboplatin
treatment and BPD-PDT. (A) Live/Dead images of nodules without
treatment, (B) after 72 hours of carboplatin treatment at 1 mM, and (C)
following BPD-PDT at 240 nM at 10 J/cm
2. Treated cultures both show a
consistent pattern of nodular core survival. Viable cells are green, while
dead cells stain red.
doi:10.1371/journal.pone.0023434.g003
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PDT regimens currently in clinical use, which lose their cytotoxic
abilities once oxygen is consumed.
EtNBS can impart cytotoxicity even in severely hypoxic
environments
The capability to impart cytotoxicity after oxygen depletion
suggested that EtNBS may be effective in severely hypoxic or even
totally anoxic environments. To test this hypothesis, day 13
nodules were incubated and treated at 100 mW/cm
2 under 100%
N2 atmosphere (Figure 8). Though the overall cytotoxicity of
EtNBS was reduced, EtNBS-PDT was still effective under severe
hypoxia, with significant cell killing observed at 20 J/cm
2
(p,.0001). While lower fluences (5–15 J/cm
2) were less effective,
they still imparted statistically significant treatment response. The
jump in cytotoxicity from 15 to 20 J/cm
2 is not entirely surprising;
PDT is a threshold phenomenon that requires a critical cellular
insult to trigger apoptosis and subsequent cellular death. To
determine if hypoxia plays any effects in modulating EtNBS dark
toxicity, a pairwise Student’s t-test was run between the dark
toxicity values collected under hypoxic and normoxic conditions.
No statistically significant difference was found, indicating that
EtNBS dark toxicity is independent of oxygen tension.
The decrease in overall cytotoxicity may arise from the fact that
Type I photochemistry can be potentiated even by low levels of O2
[34], which react with photoproducts to create cytotoxic radical
oxygen species. This result has also been replicated under 100%
CO2 atmosphere (data not shown), strongly suggesting that EtNBS
can impart cytotoxicity in the highly acidic, severely hypoxic
conditions found deep in most tumors.
Discussion
As therapies for OvCa have developed from many careful
clinical trials, the mainstay of future OvCa management will likely
rest on the three major therapeutic options used today: surgery,
platin therapeutics, and taxol-based treatment regimens. At the
same time, years of data suggest that combination treatment
regimens will be critical for future advances in battling OvCa, so it
is of great importance to strategize combinations that can address
specific therapeutic limitations. In this study, we show that the
ability of EtNBS to penetrate deeply, concentrate into large in vitro
nodules, and treat otherwise protected core cells even under severe
hypoxia is extremely promising, demonstrating that EtNBS-PDT
could be an outstanding additional tool for cancer therapy. A
treatment regimen capable of working in hypoxic or even anoxic
environments is extremely exciting for the treatment of OvCa and
other cancers, as low pO2 populations are difficult to eradicate.
EtNBS-based therapy is also promising because deep, hypoxic
tumor cells are likely inherently different than those at the
periphery. For instance, quiescent, slow-growing cells likely exist
deep in hypoxic tumor compartments, which are challenging to
treat with chemotherapeutics that typically target fast-growing
cells. Hypoxia is known to play a fundamental role in the
development of invasive and metastatic cancer as it applies
selective pressure on tumor cells. Cells that proliferate in these
hostile environments often have genetic predispositions for
adaptive survival mechanisms that make them difficult to kill
even after they migrate from the primary tumor [35]. It is also
thought that cancer stem cells naturally localize into hypoxic
environments, allowing them to escape current treatment
regimens and repopulate the tumor with treatment-resistant cells
[36]. By localizing to and effectively treating deep, acidic, and
hypoxic tumor regions, EtNBS-PDT has the capability of
eliminating these potentially resistant cancer cells early in the
treatment process.
OvCa model nodules treated with EtNBS-PDT were observed
to have irradiance-dependent treatment efficacy and spatial
cellular death patterns. The data suggests that these changes arise
from complementary activation of EtNBS’s Type I and II
Figure 4. EtNBS concentrates into the cores of 3D OvCa nodules. (A–E) Time-lapse confocal microscopy images of day 13 nodules incubated
with EtNBS at 500 nM. EtNBS is observed to penetrate into nodules rapidly under three hours. (F) Confocal image of a frozen, cyrosectioned nodule
slice showing the actual concentration of EtNBS into the nodule core. The presence of EtNBS was confirmed using hyperspectral microscopy.
doi:10.1371/journal.pone.0023434.g004
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applications. The transition from a core-specific pattern at high
irradiances to complete nodule killing (Figure 6) at low irradiances
is thought to occur due to the activation of EtNBS’s Type II,
oxygen-consuming mechanism. At high irradiances, any oxygen-
consuming photoreactions rapidly lower pO2, causing acute
hypoxia and effectively shutting down any further Type II
mediated phototherapy. At low irradiances, on the other hand,
the oxygen consumption rate is far lower. When the oxygen
consumption rate drops below the oxygen diffusion rate, EtNBS
can react via both Type I and II mechanisms, treating both the
hypoxic core cells as well as the more oxygen-enriched nodule
periphery. This dual-channel property of EtNBS will be
advantageous in vivo for treating cells present across all tumoral
oxygen partial pressures, from normoxic environments to hypoxic
regions.
The ability of EtNBS to localize to and kill nodule cores suggests
that a combination therapy approachusing EtNBS and a platin agent
could be beneficial for post-resection OvCa treatment in patients.
Previous OvCa model studies from Hasan and colleagues have
shown that PDT with BPD, followed by treatment with carboplatin,
is highly synergistic. This synergy was proposed to arise not only as
the two therapies are mechanistically distinct, but also because PDT
was able to disrupt nodule cellular architecture, allowing enhanced
carboplatin penetration [18]. We speculate that EtNBS-PDT would
likely have a similar synergy with a platin chemotherapeutic in vivo,
especially since the two agents localize to spatially different, but
overlapping, tumor microenvironments. It is thought that combina-
tiontherapywillalsoaddressthesmallviablecellularmassesobserved
when treating the OvCa models with high light doses (Figure 5C).
These scattered cells, which have been observed in the in vitro model
following treatment with other chemotherapeutics and photosensi-
tizers [27], likely represent a surviving fraction in vivo that can be
addressed through combination approaches. It is also notable that
EtNBS can be administered alongside other photosensitizers like
BPD for combination PDT regimens. Such a regimen was observed
to be synergistic in the therapy of a mouse tumor model [37], likely
because the two agents were capable of simultaneously treating
different tumor regions and cellular populations.
In conclusion, we have found that the photosensitizer EtNBS is
capable of not only homing into and concentrating in hypoxic
tumor compartments, but can also impart substantial cytotoxicity
Figure 5. Treatment response of OvCa nodules to EtNBS-PDT. (A) Bar plot of day 13 nodule viability following EtNBS-PDT across a range of
light doses. (B) Live/Dead imaging of day 13 nodules treated with 5 J/cm
2 of 652 nm light, showing nodule core cytotoxicity. (C) Day 13 nodules
treated at 20 J/cm
2. (D) Scatter plots of nodule live:dead ratio vs. volume of thousands of individual BPD and EtNBS PDT treated nodules. The axes are
plotted on a logarithmic scale. The black dotted lines are power-law fits to the data points provided as an aid to the eye. NT=no treatment control;
LO=light only control; EO=EtNBS only, without light control.
doi:10.1371/journal.pone.0023434.g005
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photosensitizer capable of physically penetrating deeply into
tumors and working via an oxygen-independent mechanism is
promising and addresses key weaknesses in many current cancer
treatment regimens. These results merit further exploration in
future studies using in vivo models of ovarian cancer. Though no
published data currently supports the safe use of EtNBS in
humans, future studies will focus on proving its safety and efficacy
towards translating this powerful agent into clinical use.
Materials and Methods
In Vitro Model of Metastatic OvCa
OVCAR-5 human OvCa cells were obtained from Thomas
Hamilton (Fox Chase Cancer Institute) and previously character-
ized by microsatellite marker analysis. Cells were grown and
maintained in complete cell media comprised of RPMI 1640
(CellGrow, Mediatech) supplemented with 10% fetal calf serum
(Gibco) and 1% of 5,000 I.U./mL penicillin/streptomycin (Cell-
Grow, Mediatech). 3D cultures were plated in either 14 mm
aperture coverslip-bottom Mattek plates (P35G-0-14-C, Mattek)
or glass-bottomed 24 well plates (W1350, Genetix) as described
previously [18,26,27,38]. Cultures were maintained in 2% GFR
supplemented complete media during growth periods.
Confocal and Multiphoton Microscopy
All confocal and multiphoton imaging experiments were carried
out on an inverted Olympus FV1000 hyperspectral laser scanning
confocal and multiphoton microscope. A tunable Titanium
Sapphire laser (MaiTai Deep See) was used for multiphoton
experiments. The inverted frame housed a programmable,
automated stage (ProScan II, Prior) that could accept 35 mm
and multiwell plates. A temperature-controlled microincubator
(Tokai-hit) was used for all confocal time-lapse imaging experi-
ments.
High-Throughput, High-Content Image-Based Viability
Assay
To visualize the detailed in vitro therapeutic response, the Live/
Dead viability assay (Invitrogen) was used as a high-throughput,
high-content imaging assay as previously described [18,27]. Image
analysis was carried out using the Matlab programming toolkit
(Mathworks) and the open-source LOCI tools. To determine the
well-by-well viability, histograms were generated for the two
fluorescence channels to determine the background intensity for
automatic subtraction. The intensities of the pixels in each channel
were then summed for a total live or dead fluorescence intensity.
The viability of each well was tabulated by dividing the total live
intensity by the sum of the live and dead intensities. All viabilities
were normalized to no treatment (NT) control wells. Statistical
analysis was accomplished using the JMP 8 software package (SAS)
using pairwise Student t-tests to calculate statistical significance.
To measure individual in vitro OvCa nodule viabilities, the
Figure 6. TL-OCT visualizes the treatment dynamics of large
OvCa model nodules following EtNBS-PDT. Each image is one
cross-sectional XZ image from the time-lapse movie (Video S2). The
nodules are observed to degrade following PDT via the appearance of
numerous highly scattering apoptotic bodies.
doi:10.1371/journal.pone.0023434.g006
Figure 7. Irradiance dependence of EtNBS-PDT on therapeutic
outcome. (A) Bar plot of nodule viability following 15 J/cm
2 PDT across
a range of irradiances. (B) Live/Dead image of a culture treated at
25 mW/cm
2 irradiance. (C) Live/Dead image of a culture treated at
300 mW/cm
2. NT=no treatment control.
doi:10.1371/journal.pone.0023434.g007
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subtracted, and then summed together into a single intensity
image. This image was then thresholded using Otsu’s method,
creating a binary image from which nodule equivalent diameters
were calculated. This binary mask was then applied to the
background-subtracted fluorescence channels to calculate the
viability of each nodule.
Live and Fixed Cell Imaging
The HypoxyProbe-1 kit (Hypoxyprobe, Inc.) was used to
visualize hypoxia in the model nodules. Pimonidazole was added
to nodules grown in Mattek dishes at a concentration of 200 mM
and incubated at 37uC for 3 hours. These plates were then stained
following a protocol modified from Debnath et al. [26,30].
Nodules were incubated at room temperature overnight with the
mouse anti-PIM antibody, followed by conjugation to AlexaFluor
568 goat anti-mouse secondary antibodies. Two Photon micros-
copy was used to image the fluorescence signal throughout the
entire nodule. AlexaFluor 568 was excited at 760 nm, and the
non-descanned emission was selected using a 570 nm LP dichroic
mirror (Omega Optics) and filtered using a 575–630 filter (Omega
Optics). Immunofluorescence staining of human fibronectin
(Sigma), collagen IV (DAKO), laminin V (Millipore), and the
Golgi protein GM130 (BD Transduction Labs) were also carried
out and imaged using confocal microscopy. ECM antibodies were
conjugated with AlexaFluor 568 labeled secondary antibodies.
GM130 was labeled with AlexaFluor 488. DAPI (Sigma) was used
to visualize cell nuclei.
The pH of cells in the model OvCa nodules was measured using
the spectral ratiometric dye SNARF-4F AM ester (Invitrogen). 3D
cultures were incubated with 20 mM SNARF-4F AM for 1 hour in
the dark prior to imaging. A confocal hyperspectral image cube
was collected for each nodule from 550 to 800 nm with a spectral
interval of 5 nm and a bandwidth of 10 nm. A Matlab script
analyzed the hyperspectral image cubes to calculate pH images by
taking the ratio of the 570 and 650 nm emission bands. The
calculated ratios were converted to pH levels using the pH-
dependent spectra provided by Invitrogen.
Imaging Apoptosis
Apoptosis imaging experiments were carried out using the
apoTRACE staining kit (Sigma-Aldrich). 24 hours post-PDT,
dishes were incubated in the dark with apoTRACE and
propidium iodide in the apoTRACE assay medium at concentra-
tions of 75 mg/ml and .5 mg/ml, respectively, for a period of
1 hour. Dishes were then washed with DPBS 16 (CellGrow,
Mediatech) and imaged immediately. The apoTRACE dye and
propidium iodide were imaged on the hyperspectral confocal
microscope. Images were processed using the ImageJ software
package. As propidium iodide stains dead cells, and apoTRACE
stains cells undergoing apoptosis, only cells displaying both dyes
will have undergone apoptotic death at the time of staining. To
visualize which cells died via apoptosis, both propidium iodide and
apoTRACE fluorescence images were first thresholded using
Otsu’s method. These images were then compared using a bitwise
AND to compute a binary image map showing only apoptotic
cells.
Cryosectioning
The in vitro OvCa nodules were sectioned using a HM 550
cryostat (Richard-Allen Scientific). To extract the nodules from the
Mattek dishes, the media was entirely removed and immediately
replaced by a 4 mm layer of O.C.T. compound (Optical Cutting
Temperature, Tissue-Tek, Sakura Finetek). Dishes were placed
over a bed of dry ice and the O.C.T. compound was allowed to
fully solidify before being transferred to a 280uC freezer. The
following day, a portion of the Matted dish plastic side-wall was
sliced off using a razor blade (VWR). The thin pointed blade of an
X-acto knife was then inserted between the bottom of the O.C.T.
disk and the top of the Mattek plastic bottom rim. The blade tip
was carefully walked around the circumference of the dish, with
great care taken to ensure the blade did not disturb the frozen
Matrigel layer. The blade was then gently twisted to separate the
O.C.T. disk and its embedded Matrigel layer from the Mattek
plate. This block of O.C.T. was then trimmed, the frozen Matrigel
block was vertically cut, and pieces of the Matrigel block were laid
into cryomolds (15 mm615 mm65 mm, Tissue-Tek) partially
filled with O.C.T. compound. These cryomolds were immediately
placed atop a bed of dry ice, frozen, sealed to lock out moisture,
and placed in a 280uC freezer overnight. Prior to cryosectioning,
cryomolds were brought to 220 C and allowed to equilibrate for
30 minutes. Frozen samples were sliced into 30 um thick slices,
placed on coverglass, mounted with a #1 coverslip to prevent
drying, and immediately imaged on the confocal hyperspectral
microscope.
Time-Lapse Optical Coherence Tomography (TL-OCT)
A highly sensitive, label-free cross-sectional imaging technology,
TL-OCT can readily visualize entire OvCa nodules, and is thus an
ideal method for following the long-term longitudinal three-
dimensional structural response to therapy. The TL-OCT system
has been described in detail elsewhere [26]. Briefly, the 15 mW
broadband output (855 nm centered, 135 nm bandwidth) of a
Broadlighter D855HP2 (Superlum) was fiber-coupled into an 80:20
fiber interferometer (AC Photonics). The 80% arm of the
interferometer was sent to a reference arm, while the 20% arm
was coupled into a home-built beam scanning inverted microscope
(Axiovert 200 M, Zeiss). A 0.15NA Zeiss56EC Plan Apo objective
Figure 8. Bar plot of EtNBS-PDT treatment response from
cultures incubated and treated under 100% N2 atmosphere.
NT=no treatment control; LO=light only control; EO=EtNBS only,
without light control. Asterisks indicate the statistical significance of
each treatment condition when compared to the EtNBS only, no light
control using a Student’s t-test: * p,.005, ** p,.007, *** p,.02, and
**** p,.0001.
doi:10.1371/journal.pone.0023434.g008
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sample was passed back into the fiber interferometer, and the final
interfered light was sent to a home-built spectrometer based on a
fast line scan camera (L104k-2048, Basler). The spectral interfer-
ogram was read by a fast frame grabber card (1428, National
Instruments) and analyzed by custom software developed using
Labview and the Intel Performance Primitives Library. Offline
image analysis and rendering was accomplished using Matlab. A
temperature-controlled microincubation chamber (DH-35i, Warn-
er Instruments) was used for all time-lapse imaging experiments. To
maintain normal culture pH, the chamber was pumped just above
positive pressure with a 5% CO2, 95% air gas mixture (Airgas).
Chemotherapy and Photodynamic Therapy
To simulate i.p. chemotherapy, carboplatin was added to 2%
Matrigel supplemented media and incubated for 72 hours at a
dose of 1 mM. This dose was calculated from the therapeutic
maximum i.p. dose of 400 mg/m
2 based on the culture surface
area [18,27]. To simulate i.p. PDT, BPD and EtNBS were added
to complete media. Nodules were incubated with 240 nM BPD for
1.5 hours prior to irradiation, following a previously established
protocol [18,27]. The optimal EtNBS concentration was deter-
mined through a toxicity screen where nodules grown on a 24 well
plate were incubated with a range of EtNBS doses.
PDT was carried out using a fiber-coupled illumination stage.
Following incubation, photosensitizer-containing media was
removed and replaced with 2% Matrigel-supplemented media
with irradiation performed immediately. BPD-PDT was carried
out using light from a 690 nm high-powered diode laser (Model
7401, HPD). All EtNBS-PDT experiments, with the sole exception
of the hypoxia experiments discussed below, used the output of a
532 nm-pumped tunable dye laser set to 652 nm (600 Series Dye
Module, Laserscope). These hypoxia EtNBS-PDT experiments
were carried out using a 670 nm diode laser (Model 7401, HPD).
To compensate for the small change in EtNBS absorption between
652 and 670 nm, a calculation was carried out using the known
laser and EtNBS spectra, resulting in a 5% relative increase in the
670 nm fluence rate. Control experiments found no difference in
EtNBS-PDT efficacy or light-induced toxicity between the
adjusted 670 nm and original 652 nm irradiances.
To investigate the ability of EtNBS to achieve cytotoxicity under
severe hypoxia, a plexiglass chamber was fabricated to feed cultures
N2 at slight positive pressure. 3.5 hours following EtNBS adminis-
tration, day 13 plates were placed inside the chamber atop a heating
plate and kept at 37uC under 100% N2 or CO2 for one hour. No
cytotoxicity was observed as a result of this incubation. At the end of
4.5 hours, the photosensitizer-containing media was replaced with
2% Matrigel-supplemented complete media which had been bubbled
with 100% N2 or CO2 for five minutes. Plates were treated using the
670 nm diode laser inside the gas chamber. Following treatment,
plates wereremoved from the chamber and returned to an incubator.
Supporting Information
Figure S1 Visualizing apoptosis in EtNBS-PDT treated
OvCa model nodules. Cultures were stained with both
propidium iodide and apoTRACE. (A) Confocal fluorescence
image of propidium iodide-stained OvCa nodules, showing
widespread destruction of cancer cells. (B) Binary image map
revealing which cells died via apoptosis. Nearly all non-viable cells
underwent apoptosis following 10 J/cm
2 EtNBS-PDT.
(TIFF)
Video S1 Time-Lapse confocal movie of EtNBS uptake
over the course of 4.5 hours. Day 13 nodules were incubated
with EtNBS and visualized using confocal microscopy during the
incubation process. EtNBS immediately binds to the surface of the
nodules and rapidly diffuses throughout the large nodules over the
course of a few hours. Small nodules fill with EtNBS within 3 hours,
while the largest nodule in the image takes nearly all 4.5 hours to
experience complete EtNBS uptake.Notethat scattering ofboth the
excitation light and emitted fluorescence significantly reduces the
apparent EtNBS concentration visualized at the center of large
OvCa nodules. The movie dimensions are 1.23 mm61.23 mm.
(MP4)
Video S2 Time-lapse optical coherence tomography
(TL-OCT) of the treatment response of day 13 nodules
following EtNBS-PDT. Each frame of the move is a single xz
cross-sectional image through three OvCa nodules. A fraction of
the entire depth profile through the Matrigel is shown. The three
nodules are seen to sit in the Matrigel bed, and the movie starts
immediately following EtNBS-PDT. The nodules are observed to
burst open from the inside, rapidly filling with highly scattering
apoptotic bodies within five hours following treatment. Cells
continue to apoptose over the next several hours, and apoptotic
bodies are observed spilling out onto the Matrigel surface. Shaking
of the thick Matrigel bed during image acquisition causes the small
amount of image warping in the movie. The opening and spilling
process seen here explains why nodules treated with EtNBS-PDT
at high fluences appear larger than nodules treated at low fluences
when viewed with a confocal microscope (Figure 7): by spilling out
on the Matrigel bed, the dying nodule spreads out over the gel
surface. The movie dimensions are 2.13 mm60.678 mm.
(MP4)
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